C5-substituted pyrido[2, 3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant1. Issue 9 (2nd September 2015)

• Record Type: Journal Article
• Authors: Xu, Tianfeng; Peng, Ting; Ren, Xiaomei; Zhang, Lianwen; Yu, Lei; Luo, Jinfeng; Zhang, Zhang; Tu, Zhengchao; Tong, Linjiang; Huang, Zhaoru; Lu, Xiaoyun; Geng, Meiyu; Xie, Hua; Ding, Jian; Ding, Ke
• Is Part Of: MedChemComm. Volume 6:Issue 9(2015:Sep.)
• Page Start: 1693
• Page End: 1697
• Publication Date: 2015-09-02
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19
• DOI: 10.1039/c5md00208g
• Languages: English
• ISSNs: 2040-2503

Abstract

<abstract abstract-type="toc"> <title> <x xml:space="preserve">Abstract</x> </title> <p> <graphic position="anchor" id="ga" xlink:href="ark:/27927/pgj2qrkxxr4" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink" />C5-substituted pyrido[2, 3-<italic>d</italic>]pyrimidin-7-ones were discovered as highly potent and specific inhibitors targeting the clinical resistance-related EGFR^L858R/T790M mutant.</p> </abstract>